Last reviewed 2026-06-10 · How we verify

Sentinel lymph node mapping in breast cancer — Treatment Landscape & Competitive Intelligence

Sentinel lymph node mapping in breast cancer (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Marketed treatment landscape

Approved drugs treating Sentinel lymph node mapping in breast cancer, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

1. Renew Pharms · 1 drug in Sentinel lymph node mapping in breast cancer

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Sentinel lymph node mapping in breast cancer:

• Sentinel lymph node mapping in breast cancer treatment updates — RSS
• Sentinel lymph node mapping in breast cancer treatment updates — Atom
• Sentinel lymph node mapping in breast cancer treatment updates — JSON

Cite this brief

Drug Landscape (2026). Sentinel lymph node mapping in breast cancer — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/sentinel-lymph-node-mapping-in-breast-cancer. Accessed 2026-06-10.

Related

• Sentinel lymph node mapping in breast cancer full disease profile — treatment pathway, diagnostics, guidelines
• Browse all CI briefs
• Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing